Fulgent Genetics Gestion

Gestion contrôle des critères 2/4

Le PDG Fulgent Genetics est Ming Hsieh, nommé en May2016, a un mandat de 8.5 ans. La rémunération annuelle totale est $ 5.31M, composée du salaire de 18.8% et des bonus 81.2%, y compris les actions et options de la société. détient directement 28.52% des actions de la société, d'une valeur de € 149.72M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.7 ans et 3.8 ans.

Informations clés

Ming Hsieh

Directeur général

US$5.3m

Rémunération totale

Pourcentage du salaire du PDG	18.8%
Durée du mandat du directeur général	8.5yrs
Propriété du PDG	28.5%
Durée moyenne d'occupation des postes de direction	4.7yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Ming Hsieh a-t-elle évolué par rapport aux bénéfices de Fulgent Genetics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$165m
Jun 30 2024	n/a	n/a	-US$163m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$5m	US$1m	-US$168m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$5m	US$948k	US$143m
Sep 30 2022	n/a	n/a	US$272m
Jun 30 2022	n/a	n/a	US$392m
Mar 31 2022	n/a	n/a	US$461m
Dec 31 2021	US$6m	US$664k	US$507m
Sep 30 2021	n/a	n/a	US$569m
Jun 30 2021	n/a	n/a	US$493m
Mar 31 2021	n/a	n/a	US$417m
Dec 31 2020	US$248k	US$240k	US$214m
Sep 30 2020	n/a	n/a	US$48m
Jun 30 2020	n/a	n/a	US$3m
Mar 31 2020	n/a	n/a	-US$459k
Dec 31 2019	US$240k	US$240k	-US$411k
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$240k	US$240k	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$240k	US$240k	-US$3m

Rémunération vs marché: La rémunération totale de Ming ($USD 5.31M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.03M ).

Rémunération et revenus: La rémunération de Ming a augmenté alors que l'entreprise n'est pas rentable.

PDG

Ming Hsieh (68 yo)

8.5yrs

Titularisation

US$5,309,167

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.52% € 149.7m
Jian Xie	COO & President	6.6yrs	US$1.79m	1.42% € 7.4m
Paul Kim	Chief Financial Officer	8.8yrs	US$1.78m	0.40% € 2.1m
Hanlin Gao	Chief Scientific Officer & Laboratory Director	8.2yrs	US$1.49m	2.8% € 14.7m
Natalie Prescott	General Counsel & Chief Privacy Officer	2.5yrs	pas de données	pas de données
Doreen Ng	VP of Operations & Compliance and GM of Houston Office	4.1yrs	pas de données	pas de données
Jakub Sram	Vice President of Business Development & Sales	9.8yrs	pas de données	pas de données
Ellen Tsui	Vice President of Human Resources	2.5yrs	pas de données	pas de données
Brandon Perthuis	Chief Commercial Officer	4.7yrs	pas de données	pas de données
Lawrence Weiss	Chief Medical Officer	3.5yrs	pas de données	pas de données
Ray Yin	President & Chief Scientific Officer of Fulgent Pharma	2yrs	pas de données	pas de données

4.7yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 7F0 est considérée comme expérimentée (ancienneté moyenne 4.7 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.52% € 149.7m
Regina Groves	Independent Non-Employee Director	1.8yrs	US$625.60k	0.0039% € 20.4k
Linda Marsh	Independent Director	5.3yrs	US$270.50k	0.061% € 320.2k
Michael Nohaile	Independent Non-Employee Director	2.3yrs	US$268.50k	0.0078% € 40.9k

3.8yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 7F0 sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Fulgent Genetics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

COO & President recently sold €543k worth of stock

Chief Financial Officer recently sold €320k worth of stock

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023)

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

New minor risk - Shareholder dilution

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

COO & President recently sold €543k worth of stock

New minor risk - Share price stability

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold €320k worth of stock

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.38 profit in 2Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Full year 2022 earnings released: EPS: US$4.77 (vs US$17.25 in FY 2021)

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.057 (vs US$4.13 in 3Q 2021)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold €94k worth of stock

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Chief Financial Officer recently sold €61k worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold €54k worth of stock

Chief Operating Officer recently sold €102k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Operating Officer recently sold €99k worth of stock

Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.

Investor sentiment improved over the past week